Supernus Pharmaceuticals, Inc. (LON:0LB2)
51.80
+0.29 (0.56%)
At close: Dec 24, 2025
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $192.10M USD in the quarter ending September 30, 2025, with 9.34% growth. This brings the company's revenue in the last twelve months to $681.54M, up 4.54% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm)
$681.54M
Revenue Growth
+4.54%
P/S Ratio
4.32
Revenue / Employee
$1.01M
Employees
674
Market Cap
2.19B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
| Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
| Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
| Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
| Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
| Dec 31, 2019 | 392.76M | -16.14M | -3.95% |
| Dec 31, 2018 | 408.90M | 106.66M | 35.29% |
| Dec 31, 2017 | 302.24M | 87.24M | 40.57% |
| Dec 31, 2016 | 215.00M | 67.54M | 45.80% |
| Dec 31, 2015 | 147.47M | 54.79M | 59.12% |
| Dec 31, 2014 | 92.68M | 80.66M | 671.10% |
| Dec 31, 2013 | 12.02M | 10.54M | 712.09% |
| Dec 31, 2012 | 1.48M | 677.00K | 84.31% |
| Dec 31, 2011 | 803.00K | 697.00K | 657.55% |
| Dec 31, 2010 | 106.00K | -37.82M | -99.72% |
| Dec 31, 2009 | 37.93M | 29.04M | 326.65% |
| Dec 31, 2008 | 8.89M | 4.66M | 109.97% |
| Dec 31, 2007 | 4.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Supernus Pharmaceuticals News
- 9 days ago - Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) to $55 | SUPN Stock News - GuruFocus
- 12 days ago - Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - The Motley Fool
- 20 days ago - Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript - Seeking Alpha
- 25 days ago - Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewsWire
- 5 weeks ago - Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 7 weeks ago - Supernus Pharmaceuticals (SUPN) Q3 2025 Earnings Reflect Robust Growth - GuruFocus
- 7 weeks ago - Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript - Seeking Alpha